{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Amlodipine", "query": { "intervention": "Placebo for Amlodipine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Amlodipine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T01:17:49.079Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03938389", "title": "The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "PreDiabetes", "Impaired Glucose Tolerance", "Obesity", "Blood Pressure" ], "interventions": [ { "name": "Sacubitril-Valsartan Tab 97-103 MG", "type": "DRUG" }, { "name": "Valsartan 160mg", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 90, "start_date": "2020-02-25", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03938389" }, { "nct_id": "NCT01368536", "title": "Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension", "Stage 2 Hypertension", "Diabetes" ], "interventions": [ { "name": "Valturna", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Chlorthalidone", "type": "DRUG" }, { "name": "Placebo of Valturna Tablet", "type": "DRUG" }, { "name": "Placebo Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 975, "start_date": "2011-05", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2013-03-21", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 95, "location_summary": "Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01368536" }, { "nct_id": "NCT00417170", "title": "Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Blood Pressure", "Metabolic Syndrome", "Insulin Resistance", "Endothelial Dysfunction" ], "interventions": [ { "name": "Aliskiren", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Placebo Aliskiren", "type": "DRUG" }, { "name": "Placebo Amlodipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2007-10", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2011-09-26", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00417170" }, { "nct_id": "NCT00739973", "title": "Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Aliskiren 150 mg tablet", "type": "DRUG" }, { "name": "Aliskiren 300 mg tablet", "type": "DRUG" }, { "name": "Amlodipine 5 mg capsule", "type": "DRUG" }, { "name": "Amlodipine 10 mg capsule", "type": "DRUG" }, { "name": "Aliskiren/amlodipine 150/5 mg tablet", "type": "DRUG" }, { "name": "Aliskiren/amlodipine 150/10 mg tablet", "type": "DRUG" }, { "name": "Aliskiren/amlodipine 300/5 mg tablet", "type": "DRUG" }, { "name": "Aliskiren/amlodipine 300/10 mg tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2694, "start_date": "2008-09", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-06-06", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00739973" }, { "nct_id": "NCT06424834", "title": "Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Angina Pectoris", "Microvascular Angina", "Vasospastic Angina", "Myocardial Bridge of Coronary Artery" ], "interventions": [ { "name": "Amlodipine", "type": "DRUG" }, { "name": "Nebivolol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-10-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06424834" }, { "nct_id": "NCT01259297", "title": "A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Events" ], "interventions": [ { "name": "Aliskiren", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Hydrochlorothiazide (HCTZ)", "type": "DRUG" }, { "name": "Placebo for Aliskiren", "type": "DRUG" }, { "name": "Placebo for Amlodipine", "type": "DRUG" }, { "name": "Placebo for Hydrochlorothiazide (HCTZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 2336, "start_date": "2011-01", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-04-08", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • Northridge, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Tucker", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01259297" }, { "nct_id": "NCT00765674", "title": "Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Aliskiren", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Hydrochlorothiazide (HCTZ)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1191, "start_date": "2008-09", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2011-05-09", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00765674" }, { "nct_id": "NCT01252238", "title": "Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Insulin Sensitivity", "Aortic Compliance", "Diastolic Function" ], "interventions": [ { "name": "Aliskiren", "type": "DRUG" }, { "name": "Valsartan and Aliskiren", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2010-06", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252238" }, { "nct_id": "NCT02034435", "title": "Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metabolic Syndrome" ], "interventions": [ { "name": "Low Salt diet plus Placebo tablet", "type": "OTHER" }, { "name": "Low Sodium diet plus Salt tablet", "type": "OTHER" }, { "name": "Epleronone", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 44, "start_date": "2013-10", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02034435" }, { "nct_id": "NCT00412113", "title": "A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dyslipidemia", "Hypertension" ], "interventions": [ { "name": "Amlodipine besylate", "type": "DRUG" }, { "name": "Amlodipine besylate/atorvastatin calcium single pill combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 245, "start_date": "2007-01", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-09-26T01:17:49.079Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412113" } ] }